Bortezomib News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bortezomib. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bortezomib Today - Breaking & Trending Today

Belantamab Mafodotin Tops Daratumumab in Multiple Myeloma

The phase 3 study findings supported belantamab mafodotin as a potential new standard of care in the second line or later among patients with released/refractory multiple myeloma. ....

Castillay Leóp , Maria Victoria Mateos , University Hospital Of Salamanca , University Hospital , Multiple Myeloma , Plasma Cell Myeloma , Proteasome Inhibitor , Biologic Therapy , Anemia Anaemia , Monoclonal Antibody ,

Examining Data from MonumenTAL-2 Study

The MonumenTAL-2 study is discussed by Rafael Fonesca, MD. ....

Conference Perspectives , Multiple Myeloma , American Society Of Hematology , Newly Diagnosed Multiple Myeloma , Triplet Therapy , Quadruplet Therapy , Perseus Trial ,

Considerations for Combination Therapy and MRD Testing in Newly Diagnosed Multiple Myeloma Patients

A medical expert navigates the treatment landscape for patients newly diagnosed with multiple myeloma. ....

Conference Perspectives , Multiple Myeloma , Combination Therapy , Newly Diagnosed Multiple Myeloma , American Society Of Hematology , Triplet Therapy , Quadruplet Therapy , Perseus Trial ,

ASH 2023: Analyzing IsKia Trial

The IsKia trial findings presented at ASH 2023 are highlighted by Dr Fonseca. ....

Conference Perspectives , Multiple Myeloma , Analyzing Iskia , American Society Of Hematology , Newly Diagnosed Multiple Myeloma , Triplet Therapy , Quadruplet Therapy , Perseus Trial ,

ASH 2023: PERSEUS Trial Overview

Rafael Fonseca, MD, discusses findings from the PERSEUS trial presented in December at ASH 2023. ....

Conference Perspectives , Multiple Myeloma , American Society Of Hematology , Newly Diagnosed Multiple Myeloma , Triplet Therapy , Quadruplet Therapy , Perseus Trial , Transplant Eligible , Master Trial , Durable Response , Four Drug Combination ,